| Indication/Trial | Patient Enrollment | Treatment(s) | Comparator | Chemotherapy | Key Efficacy Endpoint(s) |
|---|---|---|---|---|---|
| CSPC | |||||
| mCSPC2019 indication 2022 label update (overall survival final analysis)ARCHES1,3,4 |
1150† | XTANDI + GnRH therapy‡ | Placebo + GnRH therapy‡ | Prior docetaxel use allowed Docetaxel naive allowed |
Radiographic progression-free survival (BICR) (primary endpoint) Overall survival (secondary endpoint) |
| nmCSPCwith high-risk BCR2023 indication 2026 label update (overall survival final analysis)EMBARK1,5-8 |
1068 | XTANDI + GnRH therapy§|| XTANDI (single agent)|| |
Placebo + GnRH therapy§|| | Chemotherapy naive | Metastasis-free survival (BICR) (primary endpoint)¶ Overall survival (secondary endpoint) |
| CRPC | |||||
| nmCRPC2018 indication 2020 label update (overall survival final analysis)PROSPER1,9-11 |
1401 | XTANDI + GnRH therapy‡ | Placebo + GnRH therapy‡ | Chemotherapy naive | Metastasis-free survival (BICR) (primary endpoint) |
| mCRPC2016 label updateTERRAIN1,12,13 | 375 | XTANDI + GnRH therapy‡ | Bicalutamide + GnRH therapy‡ | Chemotherapy naive | Progression-free survival (ICR)# (primary endpoint) |
| mCRPC2014 indicationPREVAIL1,14,15 | 1717 | XTANDI + GnRH therapy‡ | Placebo + GnRH therapy‡ | Chemotherapy naive | Overall survival, radiographic progression-free survival (ICR) (co-primary endpoints) |
| mCRPC2012 initial approvalAFFIRM1,16,17 | 1199 | XTANDI + GnRH therapy‡ | Placebo + GnRH therapy‡ | Prior docetaxel-based chemotherapy | Overall survival (primary endpoint) |
nmCSPC with high-risk BCR is defined as nonmetastatic disease in patients who have not yet received or still respond to androgen deprivation therapy (GnRH therapy or prior bilateral orchiectomy), have experienced rising PSA after local therapy, and are at high risk for metastasis based on PSA doubling time or other clinical factors.6,18
mCSPC is defined as metastatic disease in patients who have not yet received, or who have received and still can respond to, androgen deprivation therapy (GnRH therapy or prior bilateral orchiectomy).4
CRPC is defined as disease progression on androgen deprivation therapy despite castrate levels of testosterone.17
*Estimate based on US sales and use data from September 2012 to December 2025.1,2
†Including patients with both high- and low-volume disease. High-volume disease was defined as metastases involving the viscera or, in the absence of visceral lesions, ≥ 4 bone lesions, ≥ 1 of which must be in a bony structure beyond the vertebral column and pelvic bone.1
‡Or after bilateral orchiectomy.1
§Leuprolide.1
‖Study treatment was suspended once at Week 37 if PSA was < 0.2 ng/mL at Week 36; treatment was reinitiated when PSA values increased to ≥ 2.0 ng/mL for patients with prior prostatectomy or ≥ 5.0 ng/mL for patients without prior prostatectomy. All treatment arms were eligible for treatment suspension. In the XTANDI + GnRH therapy§ and placebo + GnRH therapy§ arms, GnRH therapy§ was also suspended.1
¶Metastasis-free survival in patients randomized to receive XTANDI as a single agent compared to patients randomized to receive placebo + GnRH therapy§ was investigated as a secondary endpoint.1
#Progression-free survival was defined as the time from randomization to the first progression event, which includes radiographic disease progression, skeletal-related event, initiation of new antineoplastic therapy, and death.13
BCR, biochemical recurrence; BICR, blinded independent central review; CRPC, castration-resistant prostate cancer; FDA, U.S. Food and Drug Administration; GnRH, gonadotropin-releasing hormone; ICR, independent central review; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate cancer; nmCSPC, nonmetastatic castration-sensitive prostate cancer; PSA, prostate-specific antigen.
References: 1. XTANDI. Package insert. Northbrook, IL: Astellas Pharma US, Inc; 2026. 2. Astellas. XTANDI. Data on File. 3. U.S. Food and Drug Administration. Xtandi sNDA 203415/S-015 (ARCHES) approval letter. Published December 16, 2019. Accessed April 15, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/203415Orig1s015ltr.pdf. 4. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974-2986. doi:10.1200/JCO.19.00799. 5. U.S. Food and Drug Administration. Xtandi NDA 203415/S-022 (EMBARK) approval letter. Published November 16, 2023. Accessed January 25, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/213674Orig1s010;%20203415Orig1s022ltr.pdf. 6. Freedland SJ, De Giorgi U, Gleave M, et al. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design [published online August 12, 2021]. BMJ Open. 2021. Accessed February 5, 2025. https://bmjopen.bmj.com/content/bmjopen/11/8/e046588.full.pdf. 7. Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453-1465. doi:10.1056/NEJMoa2303974. 8. U.S. Food and Drug Administration. XTANDI sNDA 203415/S-026 and 213674/S-016 (EMBARK) supplement approval letter. Published July 24, 2026. Accessed August 24, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/203415Orig1s026;213674Orig1s016ltr.pdf. 9. U.S. Food and Drug Administration. Xtandi sNDA 203415/S-014 (PROSPER) approval letter. Published July 13, 2018. Accessed February 14, 2024.https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/203415Orig1s014ltr.pdf. 10. U.S. Food and Drug Administration. Xtandi sNDA (203415/S-016) approval letter. Published October 23, 2020. Accessed February 26, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/203415Orig1s016ltr.pdf. 11. Protocol for: Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465-2474. doi:10.1056/NEJMoa1800536. 12. U.S. Food and Drug Administration. Xtandi sNDA 203415/S-009 (TERRAIN) approval letter. Published October 20, 2016. Accessed April 15, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/203415Orig1s009ltr.pdf. 13. Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17(2):153-163. doi:10.1016/S1470-2045(15)00518-5. 14. U.S. Food and Drug Administration. Xtandi sNDA 203415/S-003 (PREVAIL) approval letter. Published September 10, 2014. Accessed February 14, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/203415Orig1s003ltr.pdf. 15. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-433. doi:10.1056/NEJMoa1405095. 16. U.S. Food and Drug Administration. Xtandi NDA 203415 approval letter. Published August 31, 2012. Accessed April 15, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/203415Orig1s000ltr.pdf. 17. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197. doi:10.1056/NEJMoa1207506. 18. Scarpato KR, Cookson MS, Dreicer R, et al. Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026). Published May 2026. Accessed May 26, 2026. https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer.